Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used to manage type 2 diabetes and chronic obesity. It mimics incretin hormones to boost insulin release from the pancreas in response to elevated blood glucose, suppress glucagon secretion, and slow gastric emptying, aiding glycemic control and weight reduction alongside diet and exercise. Approved for adults and children over 10 with type 2 diabetes, it also lowers cardiovascular risks like heart attack or stroke in high-risk patients. Administered via subcutaneous injection, it promotes sustained weight loss in obese individuals or those overweight with comorbidities